Bryn Mawr Trust Advisors LLC Sells 2,982 Shares of Merck & Co., Inc. $MRK

Bryn Mawr Trust Advisors LLC cut its holdings in Merck & Co., Inc. (NYSE:MRK) by 1.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 240,079 shares of the company’s stock after selling 2,982 shares during the quarter. Merck & Co., Inc. comprises 1.0% of Bryn Mawr Trust Advisors LLC’s holdings, making the stock its 17th biggest position. Bryn Mawr Trust Advisors LLC’s holdings in Merck & Co., Inc. were worth $19,005,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its position in shares of Merck & Co., Inc. by 144.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 49,229,283 shares of the company’s stock worth $4,418,820,000 after acquiring an additional 29,104,112 shares in the last quarter. Nuveen LLC bought a new stake in Merck & Co., Inc. in the 1st quarter valued at $991,553,000. Pacer Advisors Inc. boosted its stake in Merck & Co., Inc. by 2,240.9% in the 1st quarter. Pacer Advisors Inc. now owns 5,286,801 shares of the company’s stock worth $474,543,000 after purchasing an additional 5,060,959 shares during the period. Amundi increased its holdings in Merck & Co., Inc. by 37.1% during the 1st quarter. Amundi now owns 13,077,716 shares of the company’s stock worth $1,130,397,000 after purchasing an additional 3,542,036 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new position in Merck & Co., Inc. during the 2nd quarter worth about $258,267,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Trading Up 1.8%

NYSE MRK opened at $85.90 on Friday. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $105.07. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69. The stock has a 50 day moving average of $84.55 and a 200-day moving average of $81.98. The company has a market cap of $214.56 billion, a PE ratio of 13.24, a PEG ratio of 0.95 and a beta of 0.34.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Thursday, October 30th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.36 by $0.22. The firm had revenue of $17.28 billion for the quarter, compared to analyst estimates of $17 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. The company’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.57 earnings per share. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. On average, equities research analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Morgan Stanley boosted their price target on Merck & Co., Inc. from $98.00 to $100.00 and gave the company an “equal weight” rating in a report on Monday. Wells Fargo & Company cut their target price on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 30th. Citigroup initiated coverage on shares of Merck & Co., Inc. in a research note on Monday, October 13th. They set a “neutral” rating and a $95.00 price target for the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Wednesday, October 8th. Finally, Berenberg Bank lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and cut their price objective for the stock from $100.00 to $90.00 in a research report on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $104.47.

Insider Transactions at Merck & Co., Inc.

In related news, EVP David Michael Williams sold 8,614 shares of Merck & Co., Inc. stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $83.59, for a total transaction of $720,044.26. Following the completion of the transaction, the executive vice president owned 24,578 shares in the company, valued at approximately $2,054,475.02. This trade represents a 25.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.13% of the company’s stock.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.